Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers

Cornea

Volumn 27, Issue 1, 2008, Pages 50-55

  Holland, Edward J ^a   Bartlett, Jimmy D ^b   Paterno, Michael R ^c   Usner, Dale W ^c   Comstock, Timothy L ^c  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BAUSCH AND LOMB   (United States)

Author keywords

Dexamethasone; Ester steroid; Inflammation; Ketone steroid; Loteprednol etabonate

Indexed keywords

ANDROSTANE DERIVATIVE; ANTIINFECTIVE AGENT; DEXAMETHASONE; EYE DROPS; GLUCOCORTICOID; LOTEPREDNOL ETABONATE; TOBRAMYCIN;

ACOUSTIC MICROSCOPY; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; MULTICENTER STUDY; OCULOPLETHYSMOGRAPHY; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ACUITY;

ADOLESCENT; ADULT; AGED; ANDROSTADIENES; ANTI-BACTERIAL AGENTS; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; MALE; MICROSCOPY, ACOUSTIC; MIDDLE AGED; OPHTHALMIC SOLUTIONS; TOBRAMYCIN; TONOMETRY, OCULAR; VISUAL ACUITY;

EID: 40449102558     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31815873c7     Document Type: Article

References (31)

1. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25:33-55. (Pubitemid 34208330)
2. Thadani SM, Foster CS. Treatment of ocular inflammation in children. Paediatr Drugs. 2004;6:289-301. (Pubitemid 39423220)
3. Clark A. Basic sciences in clinical glaucoma steroids, ocular hypertension, and glaucoma. J Glaucoma. 1995;4:354-369.
4. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye. 2006;20:407-416.
5. Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging. 1999;15:439-450. (Pubitemid 30025747)
6. Lam DS, Fan DS, Ng JS, et al. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Experiment Ophthalmol. 2005;33:252-258. (Pubitemid 41602393)
7. Ng JS, Fan DS, Young AL, et al. Ocular hypertensive response to topical dexamethasone in children: a dose-dependent phenomenon. Ophthalmology. 2000;107:2097-2100.
8. Whitcup SM, Ferris FL 3rd. New corticosteroids for the treatment of ocular inflammation. Am J Ophthalmol. 1999;127:597-599. (Pubitemid 29215772)
9. Engel LS, Callegan MC, Hobden JA, et al. Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res. 1995;14:229-234.
10. Notivol R, Bertin D, Amin D, et al. Comparison of topical tobramycindexamethasone with dexamethasone-neomycin-polymyxin and neomycin- polymyxin-gramicidin for control of inflammation after cataract surgery: results of a multicenter, prospective, three-arm, randomized, double-masked, controlled, parallel-group study. Clin Ther. 2004;26: 1274-1285.
11. Bausch & Lomb. Zylet Prescribing Information. Tampa, FL: Bausch & Lomb; 2004.
12. Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. 2005;7:E820-E833.
13. Howes J, Novack GD. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, pj-91, following chronic ocular administration. J Ocul Pharmacol Ther. 1998;14:153-158. (Pubitemid 28178212)
14. Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog Retin Eye Res. 1999;18:629-667. (Pubitemid 29299153)
15. Loteprednol Etabonate Postoperative Inflammation Study Group 2. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The loteprednol etabonate postoperative inflammation study group 2. Ophthalmology. 1998;105:1780-1786.
16. Bartlett JD, Horwitz B, Laibovitz R, et al. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol. 1993;9:157-165. (Pubitemid 23187584)
17. Bartlett JD, Howes JF, Ghormley NR, et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res. 1993;12:313-321. (Pubitemid 23162150)
18. Dell SJ, Shulman DG, Lowry GM, et al. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol. 1997;123:791-797. (Pubitemid 27250926)
19. Novack GD, Howes J, Crockett RS, et al. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma. 1998;7: 266-269. (Pubitemid 29149820)
20. Dell SJ, Lowry GM, Northcutt JA, et al. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol. 1998;102:251-255.
21. Ilyas H, Slonim CB, Braswell GR, et al. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens. 2004;30:10-13. (Pubitemid 43196972)
22. Shulman DG, Lothringer LL, Rubin JM, et al. A randomized, doublemasked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology. 1999; 106:362-369. (Pubitemid 30191638)
23. Stewart R, Horwitz B, Howes J, et al. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1. J Cataract Refract Surg. 1998;24:1480-1489. (Pubitemid 28509816)
24. Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol. 1997; 123:455-464. (Pubitemid 27171850)
25. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, doublemasked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444-457. (Pubitemid 39208573)
26. Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group. Am J Ophthalmol. 1999;127:537-544.
27. Bucala R, Gallati M, Manabe S, et al. Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. Exp Eye Res. 1985;40:853- 863. (Pubitemid 16162048)
28. Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res. 1991; 10:933-937.
29. Manabe S, Bucala R, Cerami A. Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest. 1984;74: 1803-1810. (Pubitemid 15214094)
30. Herbert HM, Viswanathan A, Jackson H, et al. Risk factors for elevated intraocular pressure in uveitis. J Glaucoma. 2004;13:96-99. (Pubitemid 38372818)
31. Moorthy RS, Mermoud A, Baerveldt G, et al. Glaucoma associated with uveitis. Surv Ophthalmol. 1997;41:361-394. (Pubitemid 27214848)